Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 May 11;18(1):33.
doi: 10.1186/s13017-023-00500-z.

The unrestricted global effort to complete the COOL trial

Andrew W Kirkpatrick  1 Federico Coccolini  2 Matti Tolonen  3 Samuel Minor  4 Fausto Catena  5 Emanuel Gois Jr  6 Christopher J Doig  7 Michael D Hill  8 Luca Ansaloni  9 Massimo Chiarugi  10 Dario Tartaglia  10 Orestis Ioannidis  11 Michael Sugrue  12 Elif Colak  13 S Morad Hameed  14 Hanna Lampela  15 Vanni Agnoletti  16 Jessica L McKee  17 Naisan Garraway  18 Massimo Sartelli  19 Chad G Ball  20 Neil G Parry  21 Kelly Voght  21 Lisa Julien  22 Jenna Kroeker  18 Derek J Roberts  23 Peter Faris  24 Corina Tiruta  25 Ernest E Moore  26 Lee Anne Ammons  27 Elissavet Anestiadou  11 Cino Bendinelli  28 Konstantinos Bouliaris  29 Rosemarry Carroll  28 Marco Ceresoli  30 Francesco Favi  31 Angela Gurrado  32 Joao Rezende-Neto  33 Arda Isik  34 Camilla Cremonini  10 Silivia Strambi  10 Georgios Koukoulis  29 Mario Testini  32 Sandy Trpcic  33 Alessandro Pasculli  32 Erika Picariello  35 Fikri Abu-Zidan  36 Ademola Adeyeye  37 Goran Augustin  38 Felipe Alconchel  39 Yuksel Altinel  40 Luz Adriana Hernandez Amin  41 José Manuel Aranda-Narváez  42 Oussama Baraket  43 Walter L Biffl  44 Gian Luca Baiocchi  45 Luigi Bonavina  46 Giuseppe Brisinda  47 Luca Cardinali  48 Andrea Celotti  49 Mohamed Chaouch  50 Maria Chiarello  51 Gianluca Costa  52 Nicola de'Angelis  53 Nicolo De Manzini  54 Samir Delibegovic  55 Salomone Di Saverio  56 Belinda De Simone  57   58 Vincent Dubuisson  59 Pietro Fransvea  60 Gianluca Garulli  61 Alessio Giordano  62 Carlos Gomes  63 Firdaus Hayati  64 Jinjian Huang  65 Aini Fahriza Ibrahim  66 Tan Jih Huei  67 Ruhi Fadzlyana Jailani  68 Mansoor Khan  69 Alfonso Palmieri Luna  70 Manu L N G Malbrain  71   72 Sanjay Marwah  73 Paul McBeth  74 Andrei Mihailescu  75 Alessia Morello  76 Francesk Mulita  77 Valentina Murzi  78 Ahmad Tarmizi Mohammad  79 Simran Parmar  24 Ajay Pak  80 Michael Pak-Kai Wong  81 Desire Pantalone  82 Mauro Podda  83 Caterina Puccioni  84 Kemal Rasa  85 Jianan Ren  65 Francesco Roscio  86 Antonio Gonzalez-Sanchez  42 Gabriele Sganga  84 Maximilian Scheiterle  87 Mihail Slavchev  88 Dmitry Smirnov  89 Lorenzo Tosi  90 Anand Trivedi  91 Jaime Andres Gonzalez Vega  92 Maciej Waledziak  93 Sofia Xenaki  94 Desmond Winter  95 Xiuwen Wu  65 Andee Dzulkarnean Zakaria  96 Zaidi Zakaria  96
Affiliations
Randomized Controlled Trial

The unrestricted global effort to complete the COOL trial

Andrew W Kirkpatrick et al. World J Emerg Surg. .

Abstract

Background: Severe complicated intra-abdominal sepsis (SCIAS) has an increasing incidence with mortality rates over 80% in some settings. Mortality typically results from disruption of the gastrointestinal tract, progressive and self-perpetuating bio-mediator generation, systemic inflammation, and multiple organ failure. A further therapeutic option may be open abdomen (OA) management with negative peritoneal pressure therapy (NPPT) to remove inflammatory ascites and attenuate the systemic damage from SCIAS, although there are definite risks of leaving the abdomen open whenever it might possibly be closed. This potential therapeutic paradigm is the rationale being assessed in the Closed Or Open after Laparotomy (COOL trial) ( https://clinicaltrials.gov/ct2/show/NCT03163095 ). Initially, the COOL trial received Industry sponsorship; however, this funding mandated the use of a specific trademarked and expensive NPPT device in half of the patients allocated to the intervention (open) arm. In August 2022, the 3 M/Acelity Corporation without consultation but within the terms of the contract canceled the financial support of the trial. Although creating financial difficulty, there is now no restriction on specific NPPT devices and removing a cost-prohibitive intervention creates an opportunity to expand the COOL trial to a truly global basis. This document describes the evolution of the COOL trial, with a focus on future opportunities for global growth of the study.

Methods: The COOL trial is the largest prospective randomized controlled trial examining the random allocation of SCIAS patients intra-operatively to either formal closure of the fascia or the use of the OA with an application of an NPPT dressing. Patients are eligible if they have free uncontained intraperitoneal contamination and physiologic derangements exemplified by septic shock OR severely adverse predicted clinical outcomes. The primary outcome is intended to definitively inform global practice by conclusively evaluating 90-day survival. Initial recruitment has been lower than hoped but satisfactory, and the COOL steering committee and trial investigators intend with increased global support to continue enrollment until recruitment ensures a definitive answer.

Discussion: OA is mandated in many cases of SCIAS such as the risk of abdominal compartment syndrome associated with closure, or a planned second look as for example part of "damage control"; however, improved source control (locally and systemically) is the most uncertain indication for an OA. The COOL trial seeks to expand potential sites and proceed with the evaluation of NPPT agnostic to device, to properly examine the hypothesis that this treatment attenuates systemic damage and improves survival. This approach will not affect internal validity and should improve the external validity of any observed results of the intervention.

Trial registration: National Institutes of Health ( https://clinicaltrials.gov/ct2/show/NCT03163095 ).

Keywords: Global health; Intraperitoneal sepsis; Laparotomy; Multiple organ dysfunction; Open abdomen; Peritonitis; Randomized controlled trial; Septic shock.

PubMed Disclaimer

Conflict of interest statement

Andrew W Kirkpatrick serves as the PI of the COOL trial, as a member of the Canadian Forces Medical Services, and has consulted for the 3 m/Acelity Corporation, Zoll Medical, Innovative Trauma Care, CSL Behring, and the Statesman’s Group. Federico Coccolini, Matti Tolonen reported no declarations. Samuel Minor reported receiving research support and speaking honoraria from COOK Biotech. Emanuel Gois Jr. reported no declarations. Fausto Catena, Christopher J Doig, Michael D Hill, Luca Ansaloni, Massimo Chiurgi, Dario Tartaglia, Orestis Ioannidis reported no declarations. Michael Sugrue reported consultancy for 3 M/Acelity and Novus Scientific. Elif Colak: reported no declarations. S Morad Hameed reported being the Founder of T6 Health Systems. Hanna Lampela, Vanni Agnoletti reported no declarations. Jessica L McKee reported consultancies with the Aceso, Innovative Trauma Care, Andrew W Kirkpatrick, and Zoll Corporations, as well as consulting with the Geneva Foundation and South Trail Psychology. Naisan Garraway, Massimo Sartelli, Chad G Ball reported no declarations. Neil G Parry reported being a medical advisor for Front Line Medical Technologies – Cobra REBOA. Kelly Voght, Lisa Julien, Jenna Kroeker reported no declarations. Derek J Roberts, Peter Faris, Corina Tiruta, Ernest E Moore, Lee Ann Ammons, Elissavet Anestiadou, Cino Bendinelli, Konstantinos Bouliaris, Rosemarry Carroll, Marco Ceresoli, Francesco Favi, Angela Gurrado, Joao Rezende-Neto, Arda Isik, Camilla Cremonini, Silivia Strambi, Georgios Konstantoudakis, Mario Testini, Sandy Trpcic, Alessandro Pasculli, Erika Picariello, Fikri Abu-Zidan, Ademola Adeyeye, Goran Augustin, Felipe Alconchel, Yuksel Altinel, Luz Adriana Hernandez Amin, José Manuel-Narváez, Oussama Baraket, Walter L Biffl, Gian Luca Baiocchi, Luigi Bonavina, Giuseppe Brisinda, Luca Cardinali, Andrea Celotti, Mohamed Chaouch, Maria Michela Chiarello, Gianluca Costa, Nicola de’Angelis, Nicolo de Manzini, Samir Delibegovic, Salomone Di Saverio, Belinda De Simone reported no declarations. Dr Vincent Dubuisson received speaking honoraria from 3 M-Acelity in 2021 for a conference about how to manage an OA, at the congress of the French Association of Surgery. Pietro Fransvea, Luca Garulli, Alessio Giordano, Carlos Gomes, Firdaus Hayati, Jinjian Huang, Aini Fahriza Ibrahim, Tan Jih Huei, Ruhi Fadzlyana Jailani, Mansoor Khan, Alfonso Palmieri Luna reported no declarations. Manu L.N.G. Malbrain reported he is co-founder, past-President and current Treasurer of WSACS (The Abdominal Compartment Society, http://www.wsacs.org). He is a member of the medical advisory Board of Pulsion Medical Systems (part of Getinge group), Serenno Medical, Potrero Medical, Sentinel Medical and Baxter. He consults for BBraun, Becton Dickinson, ConvaTec, Spiegelberg, and Holtech Medical and received speaker's fees from PeerVoice. He holds stock options for Serenno and Potrero. Sanjay Marwah, Paul McBeth, Andrei Mihailescu, Alessia Morello, Francesk Mulita, Valentia Murzi, Ahmad Tarmizi Mohammad, Simran Parmar, Ajay Pal, Michael Pak-Kai Wong, Desire Pantalone, Mauro Podda, Caterina Puccioni, Kemal Rasa, Jianan Ren, Francesco Roscio, Antonio Gonzalez-Sanchez, Gabriele Sganga, Maximilian Scheiterle, Mihail Slavchev, Dmitry Smirnov, Lorenzo Tosi, Anand Trivedi, Jaime Andres Gonzalez Vega, Maciej Waledziak, Sofia Xenaki, Desmond Winter, Xiuwen Wu, Andee Dzulkarnean Zakaria reported no declarations.

Figures

Fig. 1
Fig. 1
Inclusion criteria for COOL
Fig. 2
Fig. 2
COOL trial enrollment site
Fig. 3
Fig. 3
COOL study case report form. The Case Report Form is a extensive document that can be accessed online at Study Documents – COOL Study, but Investigators are encouraged to complete the form on-line where it will be securely entered into the University of Calgary REDCap (R esearch E lectronic D ata Cap ture) database.

References

    1. Kirkpatrick AW, Coccolini F, Ansaloni L, Roberts DJ, Tolonen M, McKee JL, et al. Closed or open after source control laparotomy for severe complicated intra-abdominal sepsis (the COOL trial): study protocol for a randomized controlled trial. World J Emerg Surg. 2018;13:26. doi: 10.1186/s13017-018-0183-4. - DOI - PMC - PubMed
    1. Jawad I, Luksic I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2(1):010404. doi: 10.7189/jogh.01.010404. - DOI - PMC - PubMed
    1. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259–272. doi: 10.1164/rccm.201504-0781OC. - DOI - PubMed
    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcomes, and associated costs of care. Crit Care Med. 2001;29:1303–1310. doi: 10.1097/00003246-200107000-00002. - DOI - PubMed
    1. Slade E, Tamber PS, Vincent JL. The surviving sepsis campaign: raising awareness to reduce mortality. Crit Care. 2003;7:1–2. doi: 10.1186/cc1876. - DOI - PMC - PubMed

Publication types

Associated data